Alkermes
artistry responses in experienced melanoma patients tumor type line of therapy new cutaneous melanoma partial response evaluation of evaluation of evaluation of ongoing to with time on study weeks artistry part efficacy preliminary data ongoing study out of evaluable patients with scans total responses observed with tumor shrinkage mucosal melanoma and cutaneous melanoma majority of patients are ongoing as of march data cut inhibitors intravenous progressive disease partial response recommended phase dose stable disease reported after the data cut off and awaiting confirmation data cut off march experienced seers fee roe sails a | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
67 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Results
June 2021
artistry responses in renal cell carcinoma patients | Alkermes
Results
June 2021
artistry responses in melanoma patients | Alkermes
Related slides by other companies
Exscientia
Results
March 2024
elucidate phase ongoing in advanced solid | Exscientia
Immatics
Investor Presentation
November 2023
| Immatics
Cano Health
Investor Day
June 2022
patient physician centered clinical excellence | Cano Health
Crocs
Results
April 2023
non reconciliation | Crocs
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io